Cytokinetics Stock Forecast, Price & News

Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

Is Cytokinetics a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cytokinetics stock.
View analyst ratings for Cytokinetics or view top-rated stocks.

How has Cytokinetics' stock price been impacted by Coronavirus (COVID-19)?

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has increased by 224.4% and is now trading at $39.03.
View which stocks have been most impacted by COVID-19.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Cytokinetics.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) posted its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $0.20. The biopharmaceutical company earned $5.44 million during the quarter, compared to the consensus estimate of $5.46 million. Cytokinetics had a negative net margin of 1,061.13% and a negative trailing twelve-month return on equity of 204.75%. During the same period last year, the firm earned ($0.05) EPS.
View Cytokinetics' earnings history.

What guidance has Cytokinetics issued on next quarter's earnings?

Cytokinetics issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $23 million-$28 million, compared to the consensus revenue estimate of $28.07 million.

What price target have analysts set for CYTK?

11 brokerages have issued 12-month price targets for Cytokinetics' stock. Their forecasts range from $36.00 to $75.00. On average, they anticipate Cytokinetics' stock price to reach $50.55 in the next year. This suggests a possible upside of 29.5% from the stock's current price.
View analysts' price targets for Cytokinetics or view top-rated stocks among Wall Street analysts.

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the following people:

• Robert I. Blum, President, Chief Executive Officer & Director (LinkedIn Profile)
• Eric Terhaerdt, Vice President-Development Operations
• Ching W. Jaw, Chief Financial Officer & Senior Vice President (LinkedIn Profile)
• Fady Ibraham Malik, Executive Vice President-Research & Development (LinkedIn Profile)
• Andy Wolff, Senior VP-Clinical Research & Development

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics CEO Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among Cytokinetics' employees.

Who are some of Cytokinetics' key competitors?

Some companies that are related to Cytokinetics include Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), United Therapeutics (UTHR), CureVac (CVAC), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Legend Biotech (LEGN), Jazz Pharmaceuticals (JAZZ), Arrowhead Pharmaceuticals (ARWR), Biohaven Pharmaceutical (BHVN), Grifols (GRFS) and Zai Lab (ZLAB).
View all of CYTK's competitors.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.88%), Polar Capital Holdings Plc (3.59%), Farallon Capital Management LLC (3.26%), Wasatch Advisors Inc. (3.16%), Deerfield Management Company L.P. Series C (1.83%) and Geode Capital Management LLC (1.67%). Company insiders that own Cytokinetics stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Sandford D Smith, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends for Cytokinetics.

Which major investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including Integral Health Asset Management LLC, Alliancebernstein L.P., Wellington Management Group LLP, Farallon Capital Management LLC, Peregrine Capital Management LLC, Citigroup Inc., Polar Asset Management Partners Inc., and Assenagon Asset Management S.A.. Company insiders that have sold Cytokinetics company stock in the last year include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, and Sandford D Smith.
View insider buying and selling activity for Cytokinetics or view top insider-selling stocks.

Which major investors are buying Cytokinetics stock?

CYTK stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Franklin Resources Inc., Artal Group S.A., Frontier Capital Management Co. LLC, Point72 Asset Management L.P., Hood River Capital Management LLC, Polar Capital Holdings Plc, and Goldman Sachs Group Inc.. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Cytokinetics or or view top insider-buying stocks.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $39.03.

How much money does Cytokinetics make?

Cytokinetics has a market capitalization of $3.27 billion and generates $55.83 million in revenue each year. The biopharmaceutical company earns $-127.29 million in net income (profit) each year or ($3.09) on an earnings per share basis.

How many employees does Cytokinetics have?

Cytokinetics employs 184 workers across the globe.

When was Cytokinetics founded?

Cytokinetics was founded in 1997.

What is Cytokinetics' official website?

The official website for Cytokinetics is www.cytokinetics.com.

Where are Cytokinetics' headquarters?

Cytokinetics is headquartered at 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at [email protected], or via fax at 650-624-3010.